News headlines about Daxor (NYSE:DXR) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Daxor earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.0568318956267 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Separately, TheStreet cut shares of Daxor from a “c-” rating to a “d+” rating in a research note on Friday, April 28th.

Shares of Daxor (NYSE:DXR) opened at 6.20 on Wednesday. The company has a market cap of $23.55 million and a PE ratio of 16.19. Daxor has a 1-year low of $5.76 and a 1-year high of $9.80. The company has a 50-day moving average of $6.32 and a 200-day moving average of $7.27.

TRADEMARK VIOLATION WARNING: “Daxor (NYSE:DXR) Given Daily Media Sentiment Score of 0.12” was reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at

About Daxor

Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company engages in the short selling of stock. The Company maintains a diversified securities portfolio, which consists primarily of the common and preferred stocks of electric utility companies.

Insider Buying and Selling by Quarter for Daxor (NYSE:DXR)

Receive News & Ratings for Daxor Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor Co. and related companies with's FREE daily email newsletter.